Intravitreal ranibizumab for macular edema secondary to central retinal vein occlusion

Retina

Volumn 31, Issue 6, 2011, Pages 1060-1067

  Risard, Sarah M ^a   Pieramici, Dante J ^a   Rabena, Melvin D ^a   Basefsky, Jessica C ^a   Avery, Robert L ^a   Castellarin, Alessandro A ^a   Nasir, Ma'An A ^a   See, Robert F ^a   Couvillion, Stephen S ^a  

^a California Retina Consultants   (United States)

Author keywords

Anti VEGF; central retinal vein occlusion; Lucentis; macular edema; ranibizumab; vascular endothelial growth factor

Indexed keywords

RANIBIZUMAB;

ADULT; AGED; ARTICLE; CENTRAL RETINA VEIN OCCLUSION; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CORNEA NEOVASCULARIZATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE FUNDUS; FEMALE; HEART INFARCTION; HUMAN; MALE; OPTIC NERVE; OPTIC NERVE DISEASE; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA HEMORRHAGE; RETINA ISCHEMIA; RETINA MACULA EDEMA; TREATMENT OUTCOME; VEIN DIAMETER; VISUAL ACUITY; VISUAL IMPAIRMENT;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINA; RETINAL VEIN OCCLUSION; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 79958262136     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181fbce76     Document Type: Article

References (17)

1. Klein R, Moss SE, Meuer SM, Klein BE. The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch Ophthalmol 2008;126:513-518. (Pubitemid 351549845)
2. Cugati S, Wang JJ, Rochtchina E, Mitchell P. Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. Arch Ophthalmol 2006;124:726-732.
3. Shahsuvaryan ML, Melkonyan AK. Central retinal vein occlusion riskprofile: a case-control study. Eur J Ophthalmol 2003;13:445-452. (Pubitemid 36807129)
4. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid ofpatients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-1487. (Pubitemid 24356306)
5. Pe'er J, Folberg R, Itin A, et al. Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology 1998;105:412-416. (Pubitemid 28125092)
6. Boyd SR, Zachary I, Chakravarthy U, et al. Correlation of increased vascular endothelial growth factor with neovascula-rization and permeability in ischemic central vein occlusion. Arch Ophthalmol 2002;120:1644-1645.
7. Baseline and early natural history report. The Central Vein Occlusion Study. Arch Ophthalmol 1993;111:1087-1095.
8. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report. Ophthalmology 1995;102: 1425-1433.
9. A randomized clinical trial of early panretinal photocoagula-tion for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report. Ophthalmology 1995;102: 1434-1444.
10. Hayreh SS. Central retinal vein occlusion. Ophthalmol Clin North Am 1998;11:559-590. (Pubitemid 29013296)
11. The SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009;127:1101-1114.
12. GoffMJ, Jumper JM, Yang SS, et al. Intravitreal triamcinolone acetonide treatment of macular edema associated with central retinal vein occlusion. Retina 2006;26:896-901. (Pubitemid 44547442)
13. Pieramici DJ, Rabena MD, Castellarin A, et al. Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions. Ophthalmology 2008;115:e47-e54.
14. Spaide RF, Chang LK, Klancnik JM, et al. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol 2008;147:298-306.
15. Rouvas A, Petrou P, Vergados I, et al. Intravitreal ranibizumab (Lucentis) for treatment of central retinal vein occlusion: a prospective study. Graefes Arch Clin Exp Ophthalmol 2009; 247:1609-1616.
16. Campochiaro P, Heier J, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion; six-month primary end point results of a phase III study. Ophthalmology 2010 Jun;117:1102-1112.e1. Epub 2010 April 15.
17. Brown D, Campochiaro P, Singh R, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010 June; 117:1124-1133.e1. Epub 2010 April 9.